These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 11157037)

  • 1. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
    Chico I; Kang MH; Bergan R; Abraham J; Bakke S; Meadows B; Rutt A; Robey R; Choyke P; Merino M; Goldspiel B; Smith T; Steinberg S; Figg WD; Fojo T; Bates S
    J Clin Oncol; 2001 Feb; 19(3):832-42. PubMed ID: 11157037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
    Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T
    Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
    Bates SE; Bakke S; Kang M; Robey RW; Zhai S; Thambi P; Chen CC; Patil S; Smith T; Steinberg SM; Merino M; Goldspiel B; Meadows B; Stein WD; Choyke P; Balis F; Figg WD; Fojo T
    Clin Cancer Res; 2004 Jul; 10(14):4724-33. PubMed ID: 15269145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.
    Fracasso PM; Westervelt P; Fears CL; Rosen DM; Zuhowski EG; Cazenave LA; Litchman M; Egorin MJ
    J Clin Oncol; 2000 Mar; 18(5):1124-34. PubMed ID: 10694566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.
    Advani R; Fisher GA; Lum BL; Hausdorff J; Halsey J; Litchman M; Sikic BI
    Clin Cancer Res; 2001 May; 7(5):1221-9. PubMed ID: 11350887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
    Patnaik A; Warner E; Michael M; Egorin MJ; Moore MJ; Siu LL; Fracasso PM; Rivkin S; Kerr I; Litchman M; Oza AM
    J Clin Oncol; 2000 Nov; 18(21):3677-89. PubMed ID: 11054441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
    Kang MH; Figg WD; Ando Y; Blagosklonny MV; Liewehr D; Fojo T; Bates SE
    Clin Cancer Res; 2001 Jun; 7(6):1610-7. PubMed ID: 11410497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer.
    Chi KN; Chia SK; Dixon R; Newman MJ; Wacher VJ; Sikic B; Gelmon KA
    Invest New Drugs; 2005 Aug; 23(4):311-5. PubMed ID: 16012790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
    Rowinsky EK; Smith L; Wang YM; Chaturvedi P; Villalona M; Campbell E; Aylesworth C; Eckhardt SG; Hammond L; Kraynak M; Drengler R; Stephenson J; Harding MW; Von Hoff DD
    J Clin Oncol; 1998 Sep; 16(9):2964-76. PubMed ID: 9738565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
    Boote DJ; Dennis IF; Twentyman PR; Osborne RJ; Laburte C; Hensel S; Smyth JF; Brampton MH; Bleehen NM
    J Clin Oncol; 1996 Feb; 14(2):610-8. PubMed ID: 8636778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer.
    Fisherman JS; Cowan KH; Noone M; Denicoff A; Berg S; Poplack D; Balis F; Venzon D; McCabe M; Goldspiel B; Chow C; Ognibene FP; O'Shaughnessy J
    J Clin Oncol; 1996 Mar; 14(3):774-82. PubMed ID: 8622023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Goffin JR; Anderson IC; Supko JG; Eder JP; Shapiro GI; Lynch TJ; Shipp M; Johnson BE; Skarin AT
    Clin Cancer Res; 2005 May; 11(9):3417-24. PubMed ID: 15867243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
    Fracasso PM; Brady MF; Moore DH; Walker JL; Rose PG; Letvak L; Grogan TM; McGuire WP
    J Clin Oncol; 2001 Jun; 19(12):2975-82. PubMed ID: 11408492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer.
    Georgiadis MS; Schuler BS; Brown JE; Kieffer LV; Steinberg SM; Wilson WH; Takimoto CH; Kelley MJ; Johnson BE
    J Clin Oncol; 1997 Feb; 15(2):735-43. PubMed ID: 9053499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
    Lhommé C; Joly F; Walker JL; Lissoni AA; Nicoletto MO; Manikhas GM; Baekelandt MM; Gordon AN; Fracasso PM; Mietlowski WL; Jones GJ; Dugan MH
    J Clin Oncol; 2008 Jun; 26(16):2674-82. PubMed ID: 18509179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
    Baekelandt M; Lehne G; Tropé CG; Szántó I; Pfeiffer P; Gustavssson B; Kristensen GB
    J Clin Oncol; 2001 Jun; 19(12):2983-93. PubMed ID: 11408493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors.
    Kurata T; Shimada Y; Tamura T; Yamamoto N; Hyodo I; Saeki T; Takashima S; Fujiwara K; Wakasugi H; Kashimura M
    J Clin Oncol; 2000 Sep; 18(17):3164-71. PubMed ID: 10963645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumors.
    Garcia AA; Keren-Rosenberg S; Parimoo D; Rogers M; Jeffers S; Koda R; Muggia FM
    J Clin Oncol; 1998 Sep; 16(9):2959-63. PubMed ID: 9738564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.